NCT07177885Recruiting
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 144 (estimated)
- First submitted
- 10 Sept 2025
- Start date
- 5 Mar 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Migraine
- NCT number
- NCT07177885
What you commit to
- Study type: Observational
- Planned participants: 144
- From 5 Mar 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- Pregnant and breastfeeding women
Who the study is looking for
- Cisgender women, premenopausal, aged 18 to 50 years.
- Cisgender men, aged 18 to 50 years.
- Diagnosed with migraine (according to ICHD-3 criteria).
- Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
- Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
- All routes of administration and all dosages.
- Affiliation with a social security system.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.